Industry leaders to speak at Wood Mackenzie’s Solar & Energy Storage Summit 2025 26-03-2025, 18:00

Icelandair: Publishing of Q4 and 12M 2022 results 30-01-2023, 17:04

Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal 10-07-2024, 07:00